

1653

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. RLL-124CIPUS
---	----------------------------

In Patent Application Of: RAMPAL et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/973,265	10/9/2001	LUKTON, David	26815	1653	

Title: A STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING OMEPRAZOLE

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-124CIPUS

In Re Application: RAMPAL et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/973,265	10/9/2001	LUKTON, David	26815	1653	

Title: A STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING OMEPRAZOLE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date) _____

Signature _____

Typed or Printed Name of Person Signing Certificate _____

Certificate of Mailing by First Class MailI hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" August 23, 2004.

Date

Signature of Person Mailing Correspondence _____

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate _____

***This certificate may only be used if paying by deposit account.**
Signature

Dated: August 23, 2004

William D. Hare, Esq.

Reg. No. 44,739

Ranbaxy Inc.

600 College Road East, Suite 2100

Princeton, New Jersey 08540

Telephone: (609) 720-5378

Facsimile: (609) 514-9779

CC:



INFORMATION DISCLOSURE CITATION

Supplemental

Docket No.:
RLL-124CIPUS

Serial No.: 09/973,265

Applicants: Rampal *et al.*

Filed: 10/9/2001

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	SA1	6,605,303	8/12/2003	Karehill <i>et al.</i>	424	484	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.